-$0.43 Earnings Per Share Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter
Wall Street analysts predict that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will report earnings per share of ($0.43) for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Lexicon Pharmaceuticals’ earnings, with estimates ranging from ($0.46) to ($0.37). Lexicon Pharmaceuticals posted earnings per share of ($0.31) in the same quarter last year, which indicates a negative year over year growth rate of 38.7%. The company is scheduled to issue its next earnings report on Friday, March 2nd.
According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full-year earnings of ($1.39) per share for the current fiscal year, with EPS estimates ranging from ($1.42) to ($1.32). For the next fiscal year, analysts forecast that the business will post earnings of ($1.06) per share, with EPS estimates ranging from ($1.19) to ($0.94). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative net margin of 165.69% and a negative return on equity of 111.68%. The company had revenue of $26.94 million for the quarter, compared to analysts’ expectations of $27.97 million. During the same quarter last year, the company posted ($0.35) earnings per share. The firm’s quarterly revenue was down 2.8% on a year-over-year basis.
A number of research analysts recently weighed in on the stock. ValuEngine cut shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Wedbush restated an “outperform” rating and issued a $38.00 target price on shares of Lexicon Pharmaceuticals in a report on Thursday, November 30th. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 14th. Finally, Needham & Company LLC restated a “buy” rating and issued a $21.00 target price on shares of Lexicon Pharmaceuticals in a report on Sunday, September 17th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. Lexicon Pharmaceuticals currently has an average rating of “Hold” and an average price target of $28.50.
Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) traded up $0.40 during trading on Monday, hitting $10.29. 557,168 shares of the stock traded hands, compared to its average volume of 608,649. The stock has a market cap of $1,090.00, a PE ratio of -8.10 and a beta of 0.10. Lexicon Pharmaceuticals has a 1-year low of $8.07 and a 1-year high of $18.00. The company has a quick ratio of 1.65, a current ratio of 1.66 and a debt-to-equity ratio of 1.09.
In related news, Director Public Equities L.P. Invus acquired 180,727 shares of the stock in a transaction on Friday, November 17th. The stock was bought at an average cost of $10.11 per share, with a total value of $1,827,149.97. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Lonnel Coats acquired 10,000 shares of the stock in a transaction on Wednesday, November 15th. The stock was bought at an average cost of $9.91 per share, with a total value of $99,100.00. Following the completion of the transaction, the chief executive officer now owns 42,985 shares in the company, valued at $425,981.35. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 914,353 shares of company stock valued at $8,916,253. 5.77% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in LXRX. Cubist Systematic Strategies LLC purchased a new stake in shares of Lexicon Pharmaceuticals in the 3rd quarter worth approximately $149,000. Parametric Portfolio Associates LLC purchased a new stake in shares of Lexicon Pharmaceuticals in the 2nd quarter worth approximately $182,000. C WorldWide Group Holding A S lifted its position in shares of Lexicon Pharmaceuticals by 49.6% in the 3rd quarter. C WorldWide Group Holding A S now owns 16,146 shares of the biopharmaceutical company’s stock worth $198,000 after purchasing an additional 5,353 shares during the period. Pacad Investment Ltd. bought a new position in shares of Lexicon Pharmaceuticals during the 2nd quarter worth approximately $265,000. Finally, Legal & General Group Plc raised its stake in shares of Lexicon Pharmaceuticals by 2.6% during the 2nd quarter. Legal & General Group Plc now owns 18,570 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 465 shares in the last quarter.
TRADEMARK VIOLATION WARNING: “-$0.43 Earnings Per Share Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter” was first posted by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/0-43-earnings-per-share-expected-for-lexicon-pharmaceuticals-inc-lxrx-this-quarter/1803405.html.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.